Plasma assay sits at the center of this dementia and brain health question.

Plasma assay technology has become a cornerstone of modern Alzheimer’s disease clinical trials, enabling researchers to detect and measure early signs of cognitive decline through simple blood tests rather than invasive procedures. The most prominent examples include the Lumipulse G pTau217/β-Amyloid 1-42 plasma assay, which received FDA approval on May 16, 2025, and Roche’s Elecsys pTau181 test, which was cleared for use in primary care settings to rule out amyloid pathology. These blood-based biomarkers measure specific proteins—phosphorylated tau and beta-amyloid—that accumulate in the brain during Alzheimer’s disease progression, allowing clinicians to identify eligible trial participants and track treatment response without lumbar punctures or PET scans. This article explores how plasma assay technology works in clinical trials, why it matters for trial design, and what these advances mean for both research and patient care.

What Are Plasma Biomarkers and Why Do Alzheimer’s Clinical Trials Use Them?
How Plasma Assay Technology Measures Brain Pathology
Plasma Assays as Trial Entry Criteria and Biomarker Staging
Tracking Treatment Response with Serial Plasma Biomarker Measurements
C2N Diagnostics’ eMTBR-tau243 and Multi-Biomarker Integration
Plasma Assays Versus Cerebrospinal Fluid and PET Imaging
The Future of Plasma Assays in Alzheimer’s Research and Care
Conclusion

What Are Plasma Biomarkers and Why Do Alzheimer’s Clinical Trials Use Them?

Plasma biomarkers are measurable protein signatures in blood that reflect changes happening in the brain. Rather than waiting for cognitive symptoms to become obvious, these tests detect the underlying pathology—amyloid plaques and tau tangles—years before memory problems appear. In Alzheimer’s clinical trials, researchers depend on these biomarkers to identify participants in the right disease stage and to measure whether experimental drugs are actually slowing brain damage at a biological level.

Currently, 52 active Alzheimer’s trials (29% of the total pipeline) incorporate fluid biomarkers into their design, with 17 trials measuring amyloid (Aβ) and 17 measuring phosphorylated tau (p-tau) variants in blood samples. This widespread adoption reflects a fundamental shift in how researchers approach Alzheimer’s trials. Instead of enrolling patients based solely on cognitive complaints, trials can now screen participants using blood tests to confirm they have amyloid or tau pathology, ensuring that only people with the biological signature relevant to the drug being tested actually enroll. This precision dramatically improves the chances of detecting a drug’s true effect, because the trial population is no longer diluted with people who have cognitive symptoms from other causes (vascular damage, Lewy body disease, or simple aging).

What Are Plasma Biomarkers and Why Do Alzheimer's Clinical Trials Use Them?

How Plasma Assay Technology Measures Brain Pathology

The plasma assays used in major trials employ different technical approaches to capture the same underlying biology. The Lumipulse G assay measures the ratio of phosphorylated tau 217 (pTau217) to beta-amyloid 1-42 (Aβ42)—two proteins that are depleted from cerebrospinal fluid and enriched in plasma when they accumulate as brain deposits. Roche’s Elecsys pTau181 test measures phosphorylated tau at a different position on the protein, providing complementary information. Both tests use immunoassay technology, which relies on antibodies to capture and detect the target proteins in a small blood sample, delivering results in a matter of hours rather than the days or weeks required for older cerebrospinal fluid testing.

However, these tests are not interchangeable, and trial designers must carefully choose which biomarker best matches their research question. The TRAILBLAZER-ALZ trial, which tested the drug donanemab, used plasma pTau217 as a secondary endpoint and found a dramatic treatment response: the pTau217 level decreased by 23% on average in the treatment group over 76 weeks, while it increased by 6% in the placebo group. This clear separation between treatment and placebo signals at 12 weeks—long before cognitive decline could be reliably measured—allowed researchers to confirm that the drug was working at the biological level. The limitation is that a good biomarker response does not guarantee clinical benefit; pTau217 is a surrogate endpoint, meaning researchers are betting that slowing protein changes will ultimately slow cognitive decline, a hypothesis that still requires long-term clinical data to validate.

Plasma Assays as Trial Entry Criteria and Biomarker Staging

One of the most practical uses of plasma assay technology in clinical trials is establishing who qualifies to enroll. The FDA approvals in 2025 for both the Lumipulse and Roche tests specifically mention their utility for ruling out amyloid pathology in adults 55 and older with cognitive symptoms, making them ideal screening tools. A trial for a drug targeting tau tangles, for example, could require participants to have elevated pTau181 or pTau217 on a plasma assay—objective proof that their brain pathology matches the drug’s mechanism—rather than relying on subjective neuropsychological test scores that can be influenced by education, mood, or test-taking anxiety.

Beyond simple eligibility, researchers have developed blood-based staging models that classify participants into stages of Alzheimer’s pathology using plasma biomarkers. One such model, employing targeted mass spectrometry to measure the ratio of phosphorylated to non-phosphorylated tau peptides, achieved greater than 85% agreement across independent cohorts when classifying individuals into amyloid-negative, amyloid-positive non-cognitive, and amyloid-positive cognitive stages. This level of consistency is critical for trial design because it ensures that participants enrolled at different sites, years apart, or using slightly different lab equipment are classified into the same biological categories. A trial sponsor can therefore be confident that a participant from Mayo Clinic in Minnesota and a participant from a memory clinic in California are truly in the same disease stage, improving the trial’s statistical power and scientific credibility.

Plasma Assays as Trial Entry Criteria and Biomarker Staging

Tracking Treatment Response with Serial Plasma Biomarker Measurements

In traditional Alzheimer’s trials, researchers had to wait 18 months or longer to measure cognitive decline using bedside assessments—the gold standard outcome measure. Plasma assays compressed this timeline by allowing treatment response to be tracked every 6 months or even more frequently using a simple blood draw. Research suggests that plasma pTau217 measured at 6-month intervals can serve as a predictor of which patients are receiving clinical benefit from tau-reducing drugs, and the changes correlate with cognitive and functional decline risk.

The practical advantage is substantial: a trial sponsor can assess whether a drug is working at the biological level much earlier than waiting for cognitive scores to change, potentially shortening the trial or allowing for adaptive designs where the protocol is adjusted mid-trial based on biomarker data. However, the tradeoff is that biomarker-driven trials require participants and investigators to accept that a biological signal (protein reduction) is meaningful even if cognitive benefits take years to materialize. Some families and patients may feel let down if a drug shows a nice plasma biomarker response but cognitive outcomes lag, creating a gap between the scientific story and the patient’s lived experience.

C2N Diagnostics’ eMTBR-tau243 and Multi-Biomarker Integration

C2N Diagnostics’ eMTBR-tau243 plasma assay represents a next-generation approach that measures tau fragments produced by cutting enzymes active in Alzheimer’s-affected brains. This assay was deployed in the Phase 3 EVOKE and EVOKE+ trials, where baseline eMTBR-tau243 levels independently predicted longitudinal cognitive and functional decline. Importantly, when eMTBR-tau243 was combined with pTau217 data, the two biomarkers provided complementary information, suggesting that no single protein tells the complete story of brain pathology.

One limitation of multi-biomarker strategies is cost and logistical complexity. Running multiple assays on each blood sample increases the price per participant and requires sophisticated laboratory information systems to track and interpret results. Some sites may lack the technical capacity to handle multi-biomarker testing, potentially creating disparities in which patients have access to trials using these advanced technologies. Trial sponsors must weigh the scientific richness of multi-biomarker data against the practical reality of enrolling diverse, real-world populations.

C2N Diagnostics' eMTBR-tau243 and Multi-Biomarker Integration

Plasma Assays Versus Cerebrospinal Fluid and PET Imaging

Before plasma assays became practical, researchers relied on lumbar puncture to collect cerebrospinal fluid (CSF)—the fluid surrounding the brain and spinal cord—and measure biomarkers directly from this compartment. CSF testing is more invasive, requires a specialized procedure, carries a small risk of infection or headache, and takes longer to process. PET imaging, another traditional approach, requires expensive equipment, radiation exposure, and travel to specialized centers.

Plasma assays eliminate these barriers: a patient can give a blood sample at their regular clinic visit, and results return within hours or days. The plasma-based approach has democratized Alzheimer’s research by making it feasible to screen and monitor thousands of participants across hundreds of community-based sites, not just specialized academic medical centers. However, plasma biomarkers and CSF biomarkers do not measure identical compartments—plasma reflects both brain and peripheral sources of these proteins—so trials transitioning from CSF-based designs to plasma-based designs must carefully validate that the biomarkers correlate and have similar clinical meaning.

The Future of Plasma Assays in Alzheimer’s Research and Care

The FDA approvals and rapid adoption of plasma assays in 2025 signal a shift toward blood-based Alzheimer’s diagnosis becoming standard practice, not just a research tool. As these tests become cheaper, faster, and available at routine doctor visits, they will likely move earlier into the clinical pathway—eventually enabling screening of cognitively normal older adults to identify those at high risk of future decline, similar to how cholesterol screening works for heart disease risk.

Future plasma assay development will likely focus on multiplexing (measuring more biomarkers in a single test), improving standardization across laboratories, and shortening turnaround times. The challenge ahead is ensuring equitable access: plasma assay technology is currently expensive and concentrated in developed countries with advanced laboratory infrastructure, yet Alzheimer’s disease is a global burden affecting low- and middle-income countries disproportionately. As the technology matures and competition among manufacturers increases, costs should decline, but this remains an area where policy and investment decisions will influence whether plasma assays remain a specialized research tool or become truly accessible as a public health screening option.

Conclusion

Plasma assay technology—particularly the FDA-approved Lumipulse G and Roche Elecsys tests—has become essential to modern Alzheimer’s disease clinical trials, enabling researchers to select trial participants based on objective biological markers rather than subjective cognitive symptoms alone. These blood-based biomarkers allow researchers to track treatment response at a subclinical level, identify optimal trial candidates, and stratify participants into disease stages with remarkable consistency across populations, dramatically improving trial efficiency and scientific validity.

For patients and families, the implications are significant: plasma assays are removing barriers to Alzheimer’s research participation, allowing people to contribute to science without invasive procedures, and laying the groundwork for earlier detection and monitoring in routine clinical practice. As these technologies continue to improve and become more accessible, they will reshape how Alzheimer’s disease is diagnosed, how clinical trials are designed, and ultimately how treatment decisions are made.